Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Roche : Aspen welcomes decision to drop price probe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:52pm CEST

Aspen yesterday welcomed the Competition Commission`s decision to drop the excessive pricing investigations against it and agent Equity.

The commission yesterday halted its probe, charging that it could not sustain a case of excessive pricing against it.

However, it said its investigations into Roche, US-based technology company Genentech and Pfizer were continuing. Aspen chief executive Stephen Saad said the decision to investigate was expeditious and co-operative.

The decision follows the commissions initiation of investigations against Aspen, Roche, Genentech, Pfizer and Equity in June for suspected abuse of dominance and excessive pricing in the provision of specific cancer medicines in South Africa. When the commission announced the probe, Commissioner Tembinkosi Bonakele said the anti-graft agency had identified the health-care sector, and in particular pharmaceuticals, as a priority sector for its enforcement efforts due to the likely negative impact that anti-competitive conduct in that sector would have on consumers in general and specifically the poor and vulnerable.

Yesterday, the commission said the Aspen probe revealed that the revenue attributable to Myleran, Alkeran and Leukeran was low as the products were at the end of their lifespans. In respect of Equity, the investigation revealed that the drug, Xalkori Crizotinib, is not yet registered in South Africa. It was imported once with the permission of the Medicines Control Council. The high price charged by Equity was as a result of high cost incurred in importing the product from Germany, the commission said.

(c) 2017 TBREAK MEDIA. ALL RIGHTS RESERVED. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
PFIZER 0.71% 44.06 Delayed Quote.21.65%
ROCHE HOLDING LTD. 0.04% 235.15 Delayed Quote.-4.60%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
09/21AbbVie Gets Positive CHMP Opinion for Combination of Venclyxto With Rituximab..
DJ
09/13Roche Works to Fill Sales Gap as Biosimilars Emerge -Reuters
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/13ROCHE : FDA Approves Subcutaneous Formulation of Actemra for Use in Active Syste..
BU
09/13ROCHE : boss says Brexit and curbs on drug use pose threat to UK science
RE
09/10U.K. Health Regulator Rejects Roche's MS Drug
DJ
09/10ROCHE : faces UK pricing row over multiple sclerosis drug Ocrevus
RE
09/06FDA Extends Review Period for Roche Cancer Treatment License
DJ
09/06GENENTECH : to Present New Data from Its Extensive Lung Cancer Program at the 20..
BU
09/04With drugs pipeline in focus, Bayer considers job cuts
RE
More news
News from SeekingAlpha
09/22STOCKS TO WATCH : Calling Up Animal Spirits 
09/21Key events next week - healthcare 
09/21New opinions from EMA advisor CHMP 
09/20Arvinas Holding Prepares Terms For $100 Million IPO 
09/18Roche launches two NAVIFY clinical decision support apps 
Financials (CHF)
Sales 2018 56 475 M
EBIT 2018 19 233 M
Net income 2018 12 946 M
Debt 2018 4 708 M
Yield 2018 3,74%
P/E ratio 2018 15,54
P/E ratio 2019 15,24
EV / Sales 2018 3,67x
EV / Sales 2019 3,52x
Capitalization 203 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 259  CHF
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-4.60%211 501
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
MERCK AND COMPANY25.79%189 092
AMGEN17.94%132 756